VXRT Stock Overview
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Vaxart, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$1.07 |
| 52 Week Low | US$0.28 |
| Beta | 1.57 |
| 1 Month Change | -33.44% |
| 3 Month Change | -50.92% |
| 1 Year Change | -60.53% |
| 3 Year Change | -91.88% |
| 5 Year Change | -84.86% |
| Change since IPO | -95.78% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop
Feb 25
Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%
Jan 04Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding
Nov 16There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump
Aug 20An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued
Jun 15Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Nov 08Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Jun 30Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis
Sep 09Ray Stapleton joins Vaxart as CTO
Aug 31Vaxart shareholders approve proposal to increase number of shares
Aug 05Vaxart continues to lobby shareholders to vote to increase number of shares
Jul 29Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2
Jul 20Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success
Jul 07Vaxart: A Unique Vaccine Concern
Jun 14Shareholder Returns
| VXRT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.3% | 4.9% | 6.8% |
| 1Y | -60.5% | -8.0% | 5.9% |
Return vs Industry: VXRT underperformed the US Biotechs industry which returned -11.3% over the past year.
Return vs Market: VXRT underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| VXRT volatility | |
|---|---|
| VXRT Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VXRT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VXRT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 105 | Steven Lo | vaxart.com |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. Fundamentals Summary
| VXRT fundamental statistics | |
|---|---|
| Market cap | US$81.20m |
| Earnings (TTM) | -US$66.95m |
| Revenue (TTM) | US$28.70m |
2.8x
P/S Ratio-1.2x
P/E RatioIs VXRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VXRT income statement (TTM) | |
|---|---|
| Revenue | US$28.70m |
| Cost of Revenue | US$74.21m |
| Gross Profit | -US$45.51m |
| Other Expenses | US$21.44m |
| Earnings | -US$66.95m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | -158.58% |
| Net Profit Margin | -233.27% |
| Debt/Equity Ratio | 9.8% |
How did VXRT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 14:48 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxart, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Roger Song | Jefferies LLC |
| Cheng Li | Oppenheimer & Co. Inc. |